| For: | Guo CX, Huang X, Xu J, Zhang XZ, Shen YN, Liang TB, Bai XL. Combined targeted therapy and immunotherapy for cancer treatment. World J Clin Cases 2021; 9(26): 7643-7652 [PMID: 34621816 DOI: 10.12998/wjcc.v9.i26.7643] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v9/i26/7643.htm |
| Number | Citing Articles |
| 1 |
Si-Cong Chen, Dong-Heng Ma, Jia-Jian Zhong. Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report. World Journal of Clinical Cases 2023; 11(27): 6579-6586 doi: 10.12998/wjcc.v11.i27.6579
Abstract(913) |
Core Tip(690) |
Full Article(HTML)(1719)
|
Full Article (PDF)-19049K(197)
|
Full Article with Cover (PDF)-19348K(254)
|
Full Article (Word)-1830K(35)
|
Full Article (XML)-59K(136)
|
Audio-348K(9)
|
Peer-Review Report-223K(135)
|
Answering Reviewers-333K(116)
|
Times Cited (0)
|
Total Visits (2866)
|
Open
|
| 2 |
Tarun Kumar, Nitin Thakur, - Simran, Amit Prusti, Raj Kumar, Ajeet Kaushik, Arun Kumar. Biomimetic Nanoparticles for Targeted and Efficient Cancer Therapy: Progress, Challenges and Perspectives. International Journal of Nanomedicine 2026; doi: 10.2147/IJN.S579622
|
| 3 |
Amrita Arup Roy, Rahul Pokale, Anoushka Mukharya, Sandesh Ramchandra Jadhav, Gaurisha Alias Resha Ramnath Naik, S. P. Rachana, Viola Colaco, Paniz Hedayat, Ritu Kudarha, Srinivas Mutalik, Namdev Dhas. Core-Shell Nano Constructs for Cancer Theragnostic. 2025; doi: 10.1007/978-981-96-3025-7_15
|
| 4 |
Kiran Kumar Kolathur, Radhakanta Nag, Prathvi V Shenoy, Yagya Malik, Sai Manasa Varanasi, Ramcharan Singh Angom, Debabrata Mukhopadhyay. Molecular Susceptibility and Treatment Challenges in Melanoma. Cells 2024; 13(16) doi: 10.3390/cells13161383
|
| 5 |
Manjeera Ramadas, Nikhitha Jacob, Malaka Ameratunga, Lucy Gately. Unlocking therapeutic synergy: IDH inhibitors and immunotherapy combination in preclinical and clinical IDH mutant glioma models − A systematic review. Journal of Clinical Neuroscience 2025; 136 doi: 10.1016/j.jocn.2025.111281
|
| 6 |
Sai Manasa Varanasi, Yash Gulani, Hari Krishnareddy Rachamala, Debabrata Mukhopadhyay, Ramcharan Singh Angom. Neuropilin-1: A Multifaceted Target for Cancer Therapy. Current Oncology 2025; 32(4) doi: 10.3390/curroncol32040203
|
| 7 |
Yong-Po Zhang, Yue-Wei Tian, Jiang Geng, Xin-Hui Zhou, Meng-Ze Li, Guang-Huan Liu, Chun-Yan Gao, Ai-Qin Yue, Jin-Zhong Zhao, Wei-Jun Du. Nattokinase enhances the sensitivity of cancer cells to oxaliplatin through mitochondrial pathway and induction of apoptosis. Arabian Journal of Chemistry 2024; 17(1) doi: 10.1016/j.arabjc.2023.105478
|
| 8 |
Rose Ghemrawi, Lama Abuamer, Sedra Kremesh, Ghadeer Hussien, Rahaf Ahmed, Walaa Mousa, Ghalia Khoder, Mostafa Khair. Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy. Biomedicines 2024; 12(9) doi: 10.3390/biomedicines12092158
|
| 9 |
Muhammad Tufail, Kunxiang Gong, Bushra Ijaz, Harsh Patel, Weng-Onn Lui, Xiumei Wang, Jie Li. The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy. Drug Resistance Updates 2026; 85 doi: 10.1016/j.drup.2026.101355
|
| 10 |
Xiaoya Guan, Huina Guo, Yujia Guo, Qi Han, Zhongxun Li, Chunming Zhang. Perforin 1 in Cancer: Mechanisms, Therapy, and Outlook. Biomolecules 2024; 14(8) doi: 10.3390/biom14080910
|
| 11 |
Yashwant Kumar Ratre, Nilabh Ghritlahre, Babita Pande, Tarun Sahu, Lakkakula Suhasini Sahithi, Shashikant Swarnkar, Henu Kumar Verma. Strategic integration of immunotherapy with chemotherapy, radiotherapy, and targeted therapy in gastric cancer management: A systematic review. World Journal of Gastroenterology 2026; 32(22): 115807 doi: 10.3748/wjg.v32.i22.115807
Abstract(15) |
Core Tip(12) |
Full Article(HTML)(50)
|
Full Article (PDF)-1259K(5)
|
Full Article with Cover (PDF)-1602K(3)
|
Full Article (XML)-294K(3)
|
Audio-278K(2)
|
Peer-Review Report-456K(6)
|
Answering Reviewers-225K(5)
|
Supplementary Material-369K(4)
|
Times Cited (0)
|
Total Visits (87)
|
Open
|
| 12 |
Bisma Jan, Shafia Bashir, Abida Yousuf, Roohi Mohi-ud-din, Reyaz Hassan Mir, Mubashir Hussain Masoodi. Inflammation and Cancer. 2026; doi: 10.1016/B978-0-443-36500-3.00011-8
|
| 13 |
Ravichandran Vishwa, Bethsebie Lalduhsaki Sailo, Bandari BharathwajChetty, Mangala Hegde, Mohammed S. Alqahtani, Mohamed Abbas, Kwang Seok Ahn, Ajaikumar B. Kunnumakkara. Enhancing Anticancer Treatment Efficacy With Lycopene: A Comprehensive Review of Clinical and Preclinical Evidence. Journal of Biochemical and Molecular Toxicology 2025; 39(11) doi: 10.1002/jbt.70557
|
| 14 |
Poulami Sarkar, Manami Sardar, Olivia Sen, Stabak Das, Sreejan Manna. Therapeutic Efficacy of Nanocarrier‐Mediated Inhalable Gene Transfection for Lung Cancer. ChemistrySelect 2024; 9(37) doi: 10.1002/slct.202402903
|
| 15 |
Gaoyuan Yang, Yupeng Ren, Yuxuan Li, Yongchang Tang, Feng Yuan, Mingbo Cao, Zhiwei He, Xiaorui Su, Zheng Shi, Ziyi Hu, Meihai Deng, Jie Ren, Zhicheng Yao. Post-treatment adverse events ranking in targeted immunotherapy for hepatocellular carcinoma: A network meta-analysis based on risk probability assessment. Critical Reviews in Oncology/Hematology 2025; 211 doi: 10.1016/j.critrevonc.2025.104737
|
| 16 |
Giandomenico Roviello, Melissa Bersanelli, Martina Catalano. The Latest Developments in Biomarkers Predicting Response to Immunotherapy. Immunotherapy 2022; 14(14) doi: 10.2217/imt-2022-0053
|
| 17 |
Fatemah S. Basingab, Manar Bashanfer, Aisha A. Alrofaidi, Ahmed S. Barefah, Rawan Hammad, Hadil M. Alahdal, Jehan S. Alrahimi, Kawther A. Zaher, Sabah Hassan, Ali H. Algiraigri, Mai M. El-Daly, Saleh A. Alkarim, Alia M. Aldahlawi. T-Cell Immunoglobulin and Mucin Domain 3 (TIM-3) Gene Expression as a Negative Biomarker of B-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences 2024; 25(20) doi: 10.3390/ijms252011148
|
| 18 |
Yi Yang, Huihua Cao, Zhengping Xu, Yanmiao Dai, Xiaolan Dai, Minke Shao, Yizhou Yao, Songbing He. Precision oncology in colorectal cancer: Integrating molecular subtyping, multidisciplinary management, and emerging therapeutics. Clinical Surgical Oncology 2026; 5(1) doi: 10.1016/j.cson.2026.100119
|
| 19 |
Lisa Schlicher, Luke G. Green, Andrea Romagnani, Florian Renner. Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1297175
|
| 20 |
Shital Dange, Mohammed Musharraf Ali, Mamatha Gavisiddaiah, Jaffer Sadik Mohamed, Nasreen Sulthana, Roja Pathakota, Chandrika Balija. Expanding the Therapeutic Window in Oncology: Modern Strategies and Future Directions. Cancer Biotherapy and Radiopharmaceuticals 2026; doi: 10.1177/10849785261445412
|
| 21 |
Mariana Neves Amaral, Pedro Faísca, Hugo Alexandre Ferreira, Maria Manuela Gaspar, Catarina Pinto Reis. Current Insights and Progress in the Clinical Management of Head and Neck Cancer. Cancers 2022; 14(24) doi: 10.3390/cancers14246079
|
| 22 |
Mina Rezghi Rami, Maryam Meskini, Mohammed A. E. Elmakki. Biotechnology and Cancer Therapeutics. Interdisciplinary Biotechnological Advances 2025; doi: 10.1007/978-981-96-4959-4_10
|
| 23 |
Saeed Zivari Lashkajani, Yasaman Sadat Azad, Mohammad Taha Nami, Ali Darzi, Mahla shokouhfar, Sina Naddaf faizabadi, Maryam Diansaei, Komeil Aghazadeh-Habashi, Zahra Azimzadeh Tabrizi, Ahmad Ghorbani Vanan. Neurologic complications of immune checkpoint inhibitors: A comprehensive review. Biomedicine & Pharmacotherapy 2025; 192 doi: 10.1016/j.biopha.2025.118669
|
| 24 |
Sneha Tiwari, Sankha Bhattacharya. Understanding advanced poly (ethylene glycol)-disulphide-poly (lactic-co-glycolic acid) (PEG-SS-PLGA) nanoparticles for cutting-edge innovations, applications in smart drug delivery systems and targeted cancer therapy. Biomedical Materials 2026; 21(1) doi: 10.1088/1748-605X/ae3933
|
| 25 |
Pankaj Garg, Siddhika Pareek, Prakash Kulkarni, David Horne, Ravi Salgia, Sharad S. Singhal. Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment. Journal of Clinical Medicine 2024; 13(21) doi: 10.3390/jcm13216537
|
| 26 |
Lingyu Li, Yingli Sun. Challenges and advances of immune checkpoint therapy. Clinical and Translational Discovery 2024; 4(6) doi: 10.1002/ctd2.70001
|